Usefulness of beta-blocker therapy in patients with non-insulin- dependent diabetes mellitus and coronary artery disease

American Journal of Cardiology

Volumn 77, Issue 15, 1996, Pages 1273-1277

  Jonas, Michael ^a   Reicher Reiss, Henrietta ^a,b   Boyko, Valentina ^a   Shotan, Avraham ^a   Mandelzweig, Lori ^a   Goldbourt, Uri ^a   Behar, Solomon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIGITALIS; DIURETIC AGENT; GLUCOSE; HEART ENZYME; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PROPRANOLOL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SURVIVAL;

EID: 0030585689     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00191-9     Document Type: Article

References (25)

1. 1. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-371.
2. 2. Kjekshus J, Gilpin E, Blackey AR, Henning H, Ross J, Jr. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990;11:43-50.
3. 3. Malmberg K, Herlitz J, Hjalmarson A, Ryden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. Eur Heart J 1989;10:423-428.
4. 4. Gundersen T, Kuekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983;6:285-290.
5. 5. Waal-Manning HJ. Metabolic effect of beta-adrenoreceptor blockers. Drugs 1976;11(Supp. 1):121-126.
6. 6. Lloyd-Mostyn RH, Oram S. Modification by propranolol of cardiovascular effects of induced hypoglycaemia. Lancet 1975;2:1213-1215.
7. 7. Wright AD, Barber SG, Kendall MJ, Poole PM. Beta-adrenoreceptor-blocking drugs and blood sugar control in diabetes mellitus. Br Med J 1979;1:159.
8. 8. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, Kishon Y, Caspi A, Weisbort J, Mandelzweig L, Abinader E, Aharon L, Braun S, David D, Flich M, Friedman Y, Kristal N, Leil N, Markiewicz W, Marmor A, Palant A, Pelled B, Rabinowitz B, Reisin L, Roguin N, Rosenfeld T, Schlesinger Z, Sclarovsky S, Sherf L, Tzivoni D, Zahavi I, Zion M, Brunner D, for the Bezafibrate Infarction Prevention Study Group. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (The Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993;71:909-915.
9. 9. SAS Institute Inc., SAS Technical Report P229, SAS/STAT Software: Changes and Enhancements, Release 6.07, Cary, NC: SAS Institute Inc., 1992, 433-480.
10. 10. SAS Institute Inc. SAS/STAT User's Guide. Version 6, Fourth Edition, Volume 2, Cary, NC: SAS Institute Inc. 1989, 1027-1070.
11. 11. Moss SE, Klein R, Klein BEK. Cause-specific mortality in a population-based study of diabetes. Am J Public Health 1991;81:1158-1162.
12. 12. Ewing DJ, Campbell IW, Clarke BE. Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications. Ann Intern Med 1980;92:308-311.
13. 13. Kannel WB, McGee DC. Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979;241:2035-2038.
14. 14. Kessler II. Mortality experience of diabetic patients. A twenty-six year follow-up study. Am J Med 1971;51:715-724.
15. 15. Greenland P, Reicher-Reiss H, Goldbourt U, Behar S, and the Israeli SPRINT Investigators. In-hospital and 1-year mortality in 1,524 women after myocardial infarction. Comparison with 4,315 men. Circulation 1991;83:484-491.
16. 16. Partamian JO, Bradley FRF. Acute myocardial infarction in 258 cases of diabetes. Immediate mortality and five-year survival. N Engl J Med 1965;273:455-461.
17. 17. Herlitz J, Malmberg K, Karlson BW, Ryden L, Hjalmarson A. Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction. Acta Med Scand 1988;227:31-38.
18. 18. Kereiakes DJ. Myocardiai infarction in the diabetic patient. Clin Cardiol 1985:8:446-450.
19. 19. Savage MP, Krolewski AS, Kenien GG, Lebeis MP, Christlieb AR, Lewis SM. Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am J Cardiol 1988;62:665-669.
20. 20. Zola B, Kahn JK, Juni JE, Vinik AI. Abnormal cardiac function in diabetic patients with autonomic neuropathy in the absence of ischemic heart disease. J Clin Endocrinol Metab 1986;63:208-214.
21. 21. Malmberg K, Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J 1988;9:259-264.
22. 22. Donahue RP, Goldberg RJ, Chen Z, Gore JM, Alpert JS. The influence of sex and diabetes mellitus on survival following acute myocardial infarction: a community-wide perspective. J Clin Epidemiol 1993;46:245-252.
23. 23. Groop L, Totterman KJ, Harno K, Gordin A. Influence of beta-blocking drugs on glucose metabolism in patients with nob-insulin dependent diabetes mellitus. Acta Med Scand 1982;211:7-12.
24. 24. Steiner G. Diabetes and atherosclerosis: an overview. Diabetes 1981;30(Suppl 2):1-7.
25. 25. Ruderman NB, Haudenschild C. Diabetes as an atherogenic factor. Prog Cardiovasc Dis 1984;26:373-412.